Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1114056
PUBLISHER: Grand View Research | PRODUCT CODE: 1114056
mRNA Therapeutics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology), By Type (Prophylactic Vaccines, Therapeutic Drugs), By End-use, By Region, And Segment Forecasts, 2022 - 2030
PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
mRNA Therapeutics Market Growth & Trends:
The global mRNA therapeutics market size is expected to reach USD 37.76 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 1.7% from 2022 to 2030. One of the main factors propelling the market growth is the rising incidence of chronic and infectious diseases like diabetes, HIV, cancer, and CVDs. The growing need for therapeutic drugs and vaccinations to combat viral illnesses like Ebola, influenza, HIV, and most recently COVID-19 is expected to fuel industry growth. The COVID-19 virus has been the focus of numerous government organizations and vaccine producers, and it is anticipated that this will accelerate market expansion.
Furthermore, the availability of vaccination doses around the world is projected to increase during the forecast period as a result of multiple suppliers using novel techniques, such as combining the phase 1 and phase 2 clinical trial stages and obtaining regulatory clearances more quickly from health agencies, thus contributing to the industry growth. With the use of cutting-edge technologies, mRNA vaccines and therapeutics are generated in comparison to conventional medications. These products are less expensive to produce, more powerful against infections, and have enhanced immunogenicity. A favorable outlook for market expansion is also being created by advancements in the compositions of lipid nanoparticles for in-vivo systemic delivery of mRNA.
For instance, in March 2022, The National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) launched a phase 1 clinical trial to assess three potential HIV vaccines using a messenger RNA (mRNA) platform due to its active component and direct the cells to make a protein (or perhaps a protein fragment) that stimulates an immune response using artificial mRNA created in a lab, which enhances the vaccine with more specificity as well as robust stability. Thus, it will increase the demand and further boost the industry growth.
As another significant growth-inducing element, pharmaceutical firms are spending on mRNA technology since they can combine numerous molecules into a therapeutic drug. The market is expected to be driven by additional factors, such as significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology. For instance, Moderna and AstraZeneca are working together on a myocardial ischemia therapy using mRNA (a form of cardiac disease that develops when there is a decrease in blood flow to the heart, depriving the heart muscle of necessary oxygen). Similarly, mRNA treatments for heart disease are also being tested by Arcturus Therapeutics. Such investments are likely to supplement the market growth in the coming years.
The COVID-19 pandemic is anticipated to positively impact the industry growth. The COVID-19 vaccine is one of the diseases for which the mRNA technology is being used. In addition to its predominant use in cancer therapy, the COVID-19 vaccine is the main factor driving the market for mRNA. The mRNA firms are working hard to create COVID-19 vaccines for the next generation due to the coronavirus mutation and the potential spread of virus variants. For instance, in June 2022, The Food and Drug Administration approved the Moderna COVID-19 Vaccine and also the Pfizer & BioNTech COVID-19 Vaccine for use in children as young as 6 months old as COVID-19 preventative measures. As a result, the usage of these technologies is projected to increase during the COVID-19 pandemic and result in industry growth.
Additionally, there has been a discernible trend toward consolidation over the past few years, with players forming strategic alliances to support current R&D projects. For instance, in February 2021, building on their current partnership, GlaxoSmithKline plc and CureVac N.V. announced a new USD152.36 million agreement to create COVID-19 next-generation mRNA vaccines with the possibility for a multi-valent strategy to address numerous developing variations in a single vaccination. As additional mRNA-based therapeutic / vaccine leads exhibit proof-of-concept, go through clinical testing, and eventually hit the market, the opportunity for stakeholders involved in this specialized industry segment is likely to experience a significant increase in the predicted future.
mRNA Therapeutics Market Report Highlights:
- By application, the infectious diseases segment held a dominant share in 2021 owing to the increased patient population and awareness regarding infectious diseases
- By type, the prophylactic vaccines segment led the market in 2021. One of the key factors propelling the growth of the prophylactic vaccines business is the rising demand for prophylactic vaccinations, particularly the new COVID-19 vaccines
- By end-use, the hospitals and clinics segment captured the largest revenue share in 2021. The segment is being driven by the increasing number of patients visiting hospitals and clinics
- North America held the largest revenue share in 2021 owing to an increase in demand for COVID-19 mRNA vaccines, the existence of major players operating in the U.S., the availability of a technologically advanced healthcare research framework, and the presence of high R&D investment
- Europe is expected to grow significantly during the forecast period due to the rising occurrence of new diseases, which has prompted efforts for immunization against specific infectious diseases like COVID-19
Product Code: GVR-4-68039-957-3
Table of Contents
Chapter 1 Research Methodology
- 1.1 Market Segmentation & Scope
- 1.1.1 Estimates And Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 Gvr's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details Of Primary Research
- 1.4 Information or Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis
- 1.6.1.1 Approach 1: Commodity flow approach
- 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
- 1.6.1 Commodity Flow Analysis
- 1.7 Global Market: CAGR Calculation
- 1.8 Research Assumptions
- 1.9 List of Secondary Sources
- 1.10 List of Primary Sources
- 1.11 Objectives
- 1.11.1 Objective 1:
- 1.11.2 Objective 2:
- 1.12 List of Abbreviations
Chapter 2 Market Definitions
Chapter 3 Executive Summary
- 3.1 Market Summary
Chapter 4 Global mRNA Therapeutics Market Variables, Trends, & Scope
- 4.1 mRNA TherapeuticsMarket Lineage Outlook
- 4.1.1 Parent Market Outlook
- 4.2 Penetration and Growth Prospect Mapping
- 4.3 Regulatory Framework
- 4.4 Market Driver Analysis
- 4.4.1 Rise In Prevalence Of Cancer
- 4.4.2 Academic And Industrial Interest In mRNA
- 4.4.3 Advantages Of mRNA Vaccines
- 4.4.4 Growing Demand For Therapeutic Medicines
- 4.4.5 Outbreakof Covid-19
- 4.5 Market Restraint Analysis
- 4.5.1 Stringent Government Regulations For mRNA-Based Product Approvals
- 4.6 Porter's Five Forces Analysis
- 4.7 Pipeline Analysis
Chapter 5 mRNA Therapeutics - Segment Analysis, by Application, 2020 - 2030 (USD Million)
- 5.1 Global mRNA TherapeuticsMarket: Application Movement Analysis
- 5.2 Rare Genetic Diseases
- 5.2.1 Rare Genetic Disease Market Estimates And Forecast, 2020 - 2030 (USD Million)
- 5.3 Oncology
- 5.3.1 Oncologymarket Estimates And Forecast, 2020 - 2030 (USD Million)
- 5.4 Respiratory Diseases
- 5.4.1 Respiratory Diseasesmarket Estimates And Forecast, 2020 - 2030 (USD Million)
- 5.5 Infectious Diseases
- 5.5.1 Infectious Diseasesmarket Estimates And Forecast, 2020 - 2030 (USD Million)
- 5.6 Others
- 5.6.1 Othersmarket Estimates And Forecast, 2020 - 2030 (USD Million)
Chapter 6 mRNA Therapeutic Market- Segment Analysis, By Type, 2020 - 2030 (USD Million)
- 6.1 Global mRNA Therapeutic Market: Type Movement Analysis
- 6.2 Prophylactic Vaccines
- 6.2.1 Prophylactic Vaccinesmarket Estimates And Forecast, 2020 - 2030 (USD Million)
- 6.3 Therapeutic Vaccines
- 6.3.1 Therapeutic Vaccinesmarket Estimates And Forecast, 2020 - 2030 (USD Million)
- 6.4 Therapeutic Drugs
- 6.4.1 Therapeutic Drugsmarket Estimates And Forecast, 2020 - 2030 (USD Million)
Chapter 7 mRNA Therapeutic Market- Segment Analysis, By End-Use, 2020 - 2030 (USD Million)
- 7.1 mRNA Therapeutic Market: End-Use Movement Analysis
- 7.2 Hospitals & Clinics
- 7.2.1 Hospitals & Clinics Market Estimates And Forecast, 2020 - 2030 (USD Million)
- 7.3 Research Organizations
- 7.3.1 Research Organizationmarket Estimates And Forecast, 2020 - 2030 (USD Million)
- 7.4. Others
- 7.4.1 Others Market Estimates And Forecast, 2020 - 2030 (USD Million)
Chapter 8 mRNA Therapeutic Market: - Segment Analysis, By Region, 2020 - 2030 (USD Million)
- 8.1 mRNA Therapeutic Market:Regional Movement Analysis
- 8.2 North America
- 8.2.1 North America Market Estimates And Forecast, 2020 - 2030 (USD Million)
- 8.2.2 U.S.
- 8.2.2.1 U.S. Market Estimates And Forecast, 2020 - 2030 (USD Million)
- 8.2.3 Canada
- 8.2.3.1 Canada market Estimates And Forecast, 2020 - 2030 (USD Million)
- 8.3 Europe
- 8.3.1 Europe Market Estimates And Forecast, 2020 - 2030 (USD Million)
- 8.3.2 U.K.
- 8.3.2.1 U.K. market estimates and forecast, 2020 - 2030 (USD Million)
- 8.3.3. Germany
- 8.3.3.1 Germany market estimates and forecast, 2020 - 2030 (USD Million)
- 8.3.4 Spain
- 8.3.4.1 Spain market estimates and forecast, 2020 - 2030 (USD Million)
- 8.3.5 France
- 8.3.5.1 France market estimates and forecast, 2020 - 2030 (USD Million)
- 8.3.6 Italy
- 8.3.6.1 Italy market estimates and forecast, 2020 - 2030 (USD Million)
- 8.4 Asia Pacific
- 8.4.1 Asia Pacific market Estimates And Forecast, 2020 - 2030 (USD Million)
- 8.4.2 Japan
- 8.4.2.1 Japan market estimates and forecast, 2020 - 2030 (USD Million)
- 8.4.3 China
- 8.4.3.1 China market estimates and forecast, 2020 - 2030 (USD Million)
- 8.4.4 India
- 8.4.4.1 India market estimates and forecast, 2020 - 2030 (USD Million)
- 8.5.5 Australia
- 8.5.5.1 Australia market estimates and forecast, 2020 - 2030 (USD Million)
- 8.6.6 South Korea
- 8.6.6.1 South Korea market estimates and forecast, 2020 - 2030 (USD Million)
- 8.5 Latin America
- 8.5.1 Latin America market Estimates And Forecast, 2020 - 2030 (USD Million)
- 8.5.2 Brazil
- 8.5.2.1 Brazil market estimates and forecast, 2020 - 2030 (USD Million)
- 8.5.3 Mexico
- 8.5.3.1 Mexico market estimates and forecast, 2020 - 2030 (USD Million)
- 8.6 Middle East & Africa (MEA)
- 8.6.1 Middle East & Africa market Estimates And Forecast, 2020 - 2030 (USD Million)
- 8.6.2 South Africa
- 8.6.2.1 South Africa market estimates and forecast, 2020 - 2030 (USD Million)
- 8.6.3 Saudi Arabia
- 8.6.3.1 Saudi Arabia market estimates and forecast, 2020 - 2030 (USD Million)
- 8.7.4 UAE
- 8.7.4.1 UAE market estimates and forecast, 2020 - 2030 (USD Million)
Chapter 9 Competitive Landscape
- 9.1 Public Companies
- 9.1.1 Company Market Position Analysis
- 9.1.2 Competitive Dashboard Analysis
- 9.1.3 Strategic Framework
- 9.2 Private Companies
- 9.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
- 9.2.2 Regional Network Map
- 9.3 Company Profiles
- 9.3.1 MODERNA, INC.
- 9.3.1.1 Company Overview
- 9.3.1.2 Alere, Inc.
- 9.3.1.3 Financial Performance
- 9.3.1.4 Product Benchmarking
- 9.3.1.5 Strategic Initiatives
- 9.3.2 BIONTECH SE
- 9.3.2.1 Company Overview
- 9.3.2.2 Financial Performance
- 9.3.2.3 Product Benchmarking
- 9.3.2.4 Strategic Initiatives
- 9.3.3 CUREVAC N.V.
- 9.3.3.1 Company Overview
- 9.3.3.2 Financial Performance
- 9.3.3.3 Product Benchmarking
- 9.3.3.4 Strategic Initiatives
- 9.3.4 ARCTURUS THERAPEUTICS
- 9.3.4.1 Company Overview
- 9.3.4.2 Financial Performance
- 9.3.4.3 Product Benchmarking
- 9.4.4.4 Strategic Initiatives
- 9.3.5 TRANSLATE BIO, INC.
- 9.3.5.1 Company Overview
- 9.3.5.2 Financial Performance
- 9.3.5.3 Product Benchmarking
- 9.3.5.4 Strategic Initiatives
- 9.3.6 GSK PLC.
- 9.3.6.1 Company Overview
- 9.3.6.2 Financial Performance
- 9.3.6.3 Product Benchmarking
- 9.3.6.4 Strategic Initiatives
- 9.3.7 ARGOS THERAPEUTICS INC.
- 9.3.7.1 Company Overview
- 9.3.7.2 Financial Performance
- 9.3.7.3 Product Benchmarking
- 9.3.7.4 Strategic Initiatives
- 9.3.8 SANGAMO THERAPEUTICS, INC.
- 9.3.8.1 Company Overview
- 9.3.8.2 Financial Performance
- 9.3.8.3 Product Benchmarking
- 9.3.8.4 Strategic Initiatives
- 9.3.9 PFIZER INC.
- 9.3.9.1 Company Overview
- 9.3.9.2 Financial Performance
- 9.3.9.3 Product Benchmarking
- 9.3.9.4 Strategic Initiatives
- 9.3.10 ASTRAZENECA PLC.
- 9.3.10.1 Company Overview
- 9.3.10.2 Financial Performance
- 9.3.10.3 Product Benchmarking
- 9.3.10.4 Strategic Initiatives
- 9.3.11 CRISPR THERAPEUTICS AG
- 9.3.11.1 Company Overview
- 9.3.11.2 Financial Performance
- 9.3.11.3 Product Benchmarking
- 9.3.11.4 Strategic Initiatives
- 9.3.1 MODERNA, INC.
Product Code: GVR-4-68039-957-3
List of Tables
- TABLE 1 List of Secondary Sources
- TABLE 2 Regulatory Framework
- TABLE 3 Global mRNA therapeutics market estimates and forecasts by application, 2020 - 2030 (USD Million)
- TABLE 4 Global mRNA therapeutics market estimates and forecasts by type, 2020 - 2030 (USD Million)
- TABLE 5 mRNA therapeutics- Key market restraint
- TABLE 6 Global mRNA therapeuticsrare genetic diseases market by region, 2020 - 2030 (USD Million)
- TABLE 7 Global mRNA therapeuticoncologymarket by region, 2020 - 2030 (USD Million)
- TABLE 8 Global mRNA therapeuticrespiratory diseasesmarket by region, 2020 - 2030 (USD Million)
- TABLE 9 Global mRNA therapeuticinfectious diseasesmarket by region, 2020 - 2030 (USD Million)
- TABLE 10 Global mRNA therapeutic others market by region, 2020 - 2030 (USD Million)
- TABLE 11 Global mRNA therapeutic demand in prophylactic vaccines by region, 2020 - 2030 (USD Million)
- TABLE 12 Global mRNA therapeutic demand in therapeutic vaccines by region, 2020 - 2030 (USD Million)
- TABLE 13 Global mRNA therapeutic demand in therapeutic drugs by region, 2020 - 2030 (USD Million)
- TABLE 14 Global mRNA therapeutic demand in hospitals& clinics by region, 2020 - 2030 (USD Million)
- TABLE 15 Global mRNA therapeutic demand in research organizations by region, 2020 - 2030 (USD Million)
- TABLE 16 Global mRNA therapeutic demand in others end-use by region, 2020 - 2030 (USD Million)
- TABLE 17 North America mRNA therapeutics market by country, 2020 - 2030 (USD Million)
- TABLE 18 North America mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 19 North America mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 20 North America mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 21 U.S. mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 22 U.S. mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 23 U.S. mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 24 Canada mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 25 Canada mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 26 Canada mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 27 Europe mRNA therapeutics market by country, 2020 - 2030 (USD Million)
- TABLE 28 Europe mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 29 Europe mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 30 Europe mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 31 Germany mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 32 Germany mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 33 Germany mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 34 U.K. mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 35 U.K. mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 36 U.K. mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 37 France mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 38 France mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 39 France mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 40 Italy mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 41 Italy mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 42 Italy mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 43 Spain mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 44 Spain mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 45 Spain mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 46 Asia Pacific mRNA therapeutics market by country, 2020 - 2030 (USD Million)
- TABLE 47 Asia Pacific mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 48 Asia Pacific mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 49 Asia Pacific mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 50 China mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 51 China mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 52 China mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 53 India mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 54 India mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 55 India mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 56 Japan mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 57 Japan mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 58 Japan mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 59 Australia mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 60 Australia mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 61 Australia mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 62 South Korea mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 63 South Korea mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 64 South Korea mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 65 Latin America mRNA therapeutics market by country, 2020 - 2030 (USD Million)
- TABLE 66 Latin America mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 67 Latin America mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 68 Latin America mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 69 Brazil mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 70 Brazil mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 71 Brazil mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 72 Mexico mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 73 Mexico mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 74 Mexico mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 75 MEA mRNA therapeutics market by country, 2020 - 2030 (USD Million)
- TABLE 76 MEA mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 77 MEA mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 78 MEA mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 79 South Africa mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 80 South Africa mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 81 South Africa mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 82 Saudi Arabia mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 83 Saudi Arabia mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 84 Saudi Arabia mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
- TABLE 85 UAE mRNA therapeutics market by application, 2020 - 2030 (USD Million)
- TABLE 86 UAE mRNA therapeutics market by type, 2020 - 2030 (USD Million)
- TABLE 87 UAE mRNA therapeutics market by end-use, 2020 - 2030 (USD Million)
List of Figures
- FIG. 1 mRNA therapeutics market segmentation
- FIG. 2 Information procurement
- FIG. 3 Primary research pattern
- FIG. 4 Market research approaches
- FIG. 5 Market formulation & validation
- FIG. 6 Commodity flow analysis
- FIG. 7 mRNA therapeutics market snapshot (2021)
- FIG. 8 Market segmentation
- FIG. 9 Penetration & growth prospect mapping
- FIG. 10 Consumer behavior analysis
- FIG. 11 Market driver relevance analysis (Current & future impact)
- FIG. 12 Market restraint relevance analysis (Current & future impact)
- FIG. 13 Porter's five forces analysis
- FIG. 14 mRNA therapeutics market application outlook: Segment dashboard
- FIG. 15 mRNA therapeutic market: Application movement analysis
- FIG. 16 Rare genetic diseases market, 2020 - 2030 (USD Million)
- FIG. 17Oncologymarket, 2020 - 2030 (USD Million)
- FIG. 18 Respiratory diseases market, 2020 - 2030 (USD Million)
- FIG. 19 Infectious diseases market, 2020 - 2030 (USD Million)
- FIG. 20 Others market, 2020 - 2030 (USD Million)
- FIG. 21 mRNA therapeutics market type outlook: Segment dashboard
- FIG. 22 mRNA therapeutics market: Type movement analysis
- FIG. 23 Prophylactic vaccines market, 2020 - 2030 (USD Million)
- FIG. 24 Therapeutic vaccines market, 2020 - 2030 (USD Million)
- FIG. 25 Therapeutic drugs market, 2020 - 2030 (USD Million)
- FIG. 26 mRNA therapeutics market end-use outlook: Segment dashboard
- FIG. 27 mRNA therapeutics market: End-use movement analysis
- FIG. 28 Hospitals & clinics market, 2020 - 2030 (USD Million)
- FIG. 29 Research organizations market, 2020 - 2030 (USD Million)
- FIG. 30 Other end-uses market, 2020 - 2030 (USD Million)
- FIG. 31 Regional market: Key takeaways
- FIG. 32 Regional outlook, 2021 & 2030
- FIG. 33 North America mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 34 U.S. mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 35 Canada mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 36 Europe mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 37 U.K.mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 38 Germany mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 39 France mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 40 Italy mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 41 Spain mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 42 Asia Pacific mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 43 Japan mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 44 China mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 45 India mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 46 Australia mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 47 South Korea mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 48 Latin America mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 49 Brazil mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 50 Mexico mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 51 MEA mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 52 South Africa mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 53 Saudi Arabia mRNA therapeutics market, 2020 - 2030 (USD Million)
- FIG. 54 UAE mRNA therapeutics market, 2020 - 2030 (USD Million)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.